Risultati della ricerca - Sunfa Cheng
- Mostra 1 - 18 risultati su 18
-
1
-
2
-
3
Matrix metalloproteinase 2 and basement membrane integrity: a unifying mechanism for progressive renal injury di Sunfa Cheng, Allan S. Pollock, Rajeev Mahimkar, Jean L. Olson, David H. Lovett, Sunfa Cheng, Allan S. Pollock, Rajeev Mahimkar, Jean L. Olson, David H. Lovert
Pubblicazione 2006Artigo -
4
A functional activating protein 1 (AP-1) site regulates matrix metalloproteinase 2 (MMP-2) transcription by cardiac cells through interactions with JunB-Fra1 and JunB-FosB heterodi... di Marina Bergman, Sunfa Cheng, Norman Honbo, Lucia Piacentini, Joel S. Karliner, David H. Lovett
Pubblicazione 2003Artigo -
5
-
6
-
7
Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double‐blind, placebo‐controlled study di Takao Takeshima, Fumihiko Sakai, Koichi Hirata, Noboru Imai, Yasuhiko Matsumori, Ryuji Yoshida, Cheng Peng, Sunfa Cheng, Daniel D. Mikol
Pubblicazione 2021Artigo -
8
Cinacalcet Reduces Serum Calcium Concentrations in Patients with Intractable Primary Hyperparathyroidism di Claudio Marcocci, Philippe Chanson, Dolores Shoback, John P. Bilezikian, Laureano Fernández‐Cruz, Jacques Orgiazzi, Christoph Henzen, Sunfa Cheng, Lulu Ren Sterling, John Lu, Munro Peacock
Pubblicazione 2009Artigo -
9
-
10
Erenumab in chronic migraine di Richard B. Lipton, Stewart J. Tepper, Uwe Reuter, Stephen D. Silberstein, Walter F. Stewart, Jon Nilsen, Dean Leonardi, Pooja Desai, Sunfa Cheng, Daniel D. Mikol, Robert Lenz
Pubblicazione 2019Artigo -
11
Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial di Messoud Ashina, Peter J. Goadsby, Uwe Reuter, Stephen D. Silberstein, David W. Dodick, Fei Xue, Feng Zhang, Gabriel Paiva da Silva Lima, Sunfa Cheng, Daniel D. Mikol
Pubblicazione 2021Artigo -
12
Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine di Messoud Ashina, Peter J. Goadsby, Uwe Reuter, Stephen D. Silberstein, David W. Dodick, Gregory A. Rippon, Jan Klatt, Fei Xue, Victoria Chia, Feng Zhang, Sunfa Cheng, Daniel D. Mikol
Pubblicazione 2019Artigo -
13
Vascular safety of erenumab for migraine prevention di David Kudrow, Julio Pascual, Paul Winner, David W. Dodick, Stewart J. Tepper, Uwe Reuter, Frank Hong, Jan Klatt, Feng Zhang, Sunfa Cheng, Hernàn Picard, Osa Eisele, Julie Wang, Jonathan N. Latham, Daniel D. Mikol
Pubblicazione 2019Artigo -
14
Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism di Geoffrey A. Block, David A. Bushinsky, Sunfa Cheng, John Cunningham, Bastian Dehmel, Tilman B. Drüeke, Markus Ketteler, Reshma Kewalramani, Kévin Martin, Sharon M. Moe, Uptal D. Patel, Justin Silver, Yan Sun, Hao Wang, Glenn M. Chertow
Pubblicazione 2017Artigo -
15
Practice patterns on the management of secondary hyperparathyroidism in the United States: Results from a modified Delphi panel di David Henner, Beatrice Drambarean, Teresa Gerbeling, Jessica Kendrick, William T. Kendrick, Lisa Koester-Wiedemann, Thomas L. Nickolas, Anjay Rastogi, Anis Abdul Rauf, Brenda Dyson, Michael C. Singer, Pooja Desai, Kathleen M. Fox, Sunfa Cheng, William G. Goodman
Pubblicazione 2025Artigo -
16
Early onset of efficacy with erenumab in patients with episodic and chronic migraine di Todd J. Schwedt, Uwe Reuter, Stewart J. Tepper, Messoud Ashina, David Kudrow, Gregor Broessner, Guy Boudreau, Peter McAllister, Thuy Vu, Feng Zhang, Sunfa Cheng, Hernàn Picard, Shihua Wen, Joseph M. Kahn, Jan Klatt, Daniel D. Mikol
Pubblicazione 2018Artigo -
17
Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure di Karl Swedberg, James B. Young, Inder S. Anand, Sunfa Cheng, Akshay S. Desai, Rafael Díaz, Aldo P. Maggioni, John J.V. McMurray, Christopher O’Connor, Marc A. Pfeffer, Scott D. Solomon, Yan Sun, Michał Tendera, Dirk J. van Veldhuisen
Pubblicazione 2013Artigo -
18
Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED‐HF study di Paul Welsh, Lei Kou, Changhong Yu, Inder S. Anand, Dirk J. van Veldhuisen, Aldo P. Maggioni, Akshay S. Desai, Scott D. Solomon, Marc A. Pfeffer, Sunfa Cheng, Lars Gullestad, Pål Aukrust, Thor Ueland, Karl Swedberg, James B. Young, Michael W. Kattan, Naveed Sattar, John J.V. McMurray
Pubblicazione 2017Artigo
Strumenti per la ricerca:
Soggetti correlati
Medicine
Internal medicine
Migraine
Pathology
Alternative medicine
Placebo
Adverse effect
Biology
Biochemistry
Cell biology
Chronic Migraine
Clinical trial
Hyperparathyroidism
Randomized controlled trial
Calcium
Chemistry
Cinacalcet
Clinical endpoint
Parathyroid hormone
Secondary hyperparathyroidism
Tolerability
Urology
Calcimimetic
Cardiology
Endocrinology
Extracellular matrix
Fibrosis
Gastroenterology
Gene
Heart failure